A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma - Poll - MDSpire

Evaluation of Sapanisertib in Patients with Advanced Anaplastic and Radioiodine-Refractory Differentiated Thyroid Cancer: A Phase I/II Study

  • By

  • Kartik Sehgal

  • Anthony Serritella

  • Mofei Liu

  • Anne ONeill

  • Chaitali Nangia

  • Theodora Pappa

  • Michael J Demeure

  • Francis P Worden

  • Robert I Haddad

  • Jochen Lorch

  • June 29, 2024

Share

Original Source(s)

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

  • by Kartik Sehgal, Anthony Serritella, Mofei Liu, Anne ONeill, Chaitali Nangia, Theodora Pappa, Michael J Demeure, Francis P Worden, Robert I Haddad, Jochen Lorch

  • June 29, 2024

Related Content

Metagenomic and metabolomic profiling in primary aldosteronism with coexisting obstructive sleep apnea

Explainable machine learning for osteoporosis detection in patients with osteopenia: model development and validation using routine clinical data from an Asian cohort

Integrative functional bioinformatic analysis of NAD+-associated protein coding genes in adipose tissue (dys)function – evidence from targeted rodent transcriptomic studies